The central nervous system involvement, in terms of a maladaptive sensory-motor plasticity, is well known in patients with dystrophic myotonias (DMs). To date, there are no data suggesting a central nervous system involvement in non-dystrophic myotonias (NDMs).
Objective:
To investigate sensory-motor plasticity in patients with Myotonia Congenita (MC) and Paramyotonia Congenita (PMC) with or without mexiletine.
Methods:
Twelve patients with a clinical, genetic, and electromyographic evidence of MC, fifteen with PMC, and 25 healthy controls (HC) were included in the study. TMS on both primary motor cortices (M1) and a rapid paired associative stimulation (rPAS) paradigm were carried out to assess M1 excitability and sensory-motor plasticity.
Results:
patients showed a higher cortical excitability and a deterioration of the topographic specificity of rPAS aftereffects, as compared to HCs. There was no correlation among neurophysiological and clinical-demographic characteristics. Noteworthy, the patients who were under mexiletine showed a minor impairment of the topographic specificity of rPAS aftereffects as compared to those who did not take the drug.
Conclusion:
our findings could suggest the deterioration of cortical sensory-motor plasticity in patients with NDMs as a trait of the disease.
AppsD.K. (1992). Ionic channels of excitable membranes2, Federation of European Biochemical SocietiesLetters, 306, 277–278.
2.
BartelP.R, LotzB.P, & Van der MeydenC.H. (1984). Short-latency somatosensory evoked potentials in dystrophiamyotonica. Journal of Neurology, Neurosurgery, and Psychiatry, 47, 524–529.
3.
BeckS, & HallettM. (2011). Surround inhibition in the motorsystem. Experimental Brain Research, 210, 165–172.
4.
BugiardiniE, RivoltaI, BindaA, Soriano CamineroA, CirilloF, CintiA, GiovannoniR, BottaA, CardaniR, WicklundM.P, & MeolaG. (2015). SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscular Disorders, 25, 301–307.
5.
CannonS.C. (1996). Ion-channel defects and aberrant excitabilityin myotonia and periodic paralysis. Trends in Neuroscience, 19, 3–10.
6.
CardaniR, GiagnacovoM, BottaA, RinaldiF, MorganteA, UddB, RaheemO, PenttiläS, SuominenT, RennaL.V, SansoneV, BugiardiniE, NovelliG, & MeolaG. (2012). Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. Journal of Neurology, 259, 2090–2099.
7.
CarsonR.G, & KennedyN.C. (2013). Modulation of humancorticospinal excitability by paired associative stimulation. Frontiers in Human Neuroscience, 7, 823.
8.
CatterallW.A. (1987). Common modes of drugs action on Na+ channels: Local anesthetics, antiarrhythmic and anticonvulsants. Trends in Pharmacological Sciences, 8, 57–65.
9.
CatterallW.A, & MackieK. (2001) Local anesthetics, In: HardmanJ.G., LimbirdL.E., MolinoffmB., RuddonR.W., GilmanA.G.(Eds.), Goodman and Gilman’s the Pharmacological Basis ofTherapeutics (pp. 367–384). New York: Macmillan Publishing Co.
10.
ChabalC, JacobsonL, MarianoA, ChaneyE, & BritellC.W. (1992). The use of oral mexiletine for the treatment of pain afterperipheral nerve injury. Anesthesiology, 76, 513–517.
11.
De LucaA, NatuzziF, DesaphyJ.F, LoniG, LentiniG, FranchiniC, TortorellaV, & CamerinoD.C. (2000). Molecular determinants of mexiletine structure for potent and use-dependentblock of skeletal muscle sodium channels. MolecularPharmacology, 57, 268–77.
12.
De LucaA., NatuzziF., FalconeG., DurantiA., LentiniG., Franchini
.C., TortorellaV., & CamerinoD.C. (1997a). Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide. Naunyn-Schmiedeberg’s Archives of Pharmacology, 356, 777–787.
13.
De LucaA, PiernoS, LiantonioA, DesaphyJ.F, NatuzziF, DidonnaM.P, FerranniniE, JockuschH, FranchiniC, LentiniG, CorboF, TortorellaV, & CamerinoD.C. (2004). New potentmexiletine and tocainide analogues evaluated in vivo and in vitro asantimyotonic agents on the myotonic ADR mouse. Neuromuscular Disorders, 14, 405–416.
14.
De LucaA., PiernoS., NatuzziF., FranchiniC., DurantiA., LentiniG., TortorellaV., JockuschH., & CamerinoD.C., (1997b). Evaluation of the antimyotonic activity of mexiletine andsome new analogs on sodium currents of single muscle fibers and onthe abnormal excitability of the myotonic ADR mouse. Journal of Pharmacology and Experimental Therapeutics, 282, 93–100.
15.
De LucaA, PröbstleT, BrinkmeierH, & RüdelR. (1991). The different use dependences of tocainide and benzocaineare correlated with different effects on sodium channelinactivation. Naunyn-Schmiedeberg’s Archives of Pharmacology, 344, 596–601.
16.
DesaphyJ.F, De LucaA, TortorellaP, De VitoD, GeorgeA.LJr, & Conte CamerinoD. (2001). Gating of myotonic Na channelmutants defines the response to mexiletine and a potent derivative. Neurology, 57, 1849–1857.
17.
EyreJ.a, MillerS, & RameshV. (1991). Constancy of centralconduction delays during development in man: Investigation of motorand somatosensory pathways. The Journal of Physiology, 434, 441–452.
18.
FarmerL.M, LeB.N, & NelsonD.J. (2013). CLC-3 chloridechannels moderate long-term potentiation at Schaffer collateral-CA1 synapses. The Journal of Physiology, 591, 1001–1015.
19.
FeldmanD.E. (2012). The spike-timing dependence of plasticity. Neuron, 75, 556–571.
GrantA.O, & WendtD.J. (1992). Block and modulation of cardiacNa+ channels by antiarrhythmic drugs, neurotransmitters andhormones. Trends in Pharmacological Sciences, 13, 352–358.
22.
HamiltonM. (1959). The assessment of anxiety states by rating. The British Journal of Medical Psychology, 32, 50–55.
23.
HamiltonM. (1960). A rating scale for depression. Neurosurgery, and Psychiatry, 23, 56–62.
24.
HeatwoleC.R, StatlandJ.M, & LogigianE.L. (2013). Thediagnosis and treatment of myotonic disorders. Muscle Nerve, 47, 632–648.
25.
HilleB. (1977). Local anesthetics: Hydrophilic and hydrophobicpathways for the drug-receptor reaction. The Journal of GeneralPhysiology, 69, 497–515.
26.
HorgaA, Raja RayanD.L, MatthewsE, SudR, FialhoD, DurranS.C, BurgeJ.A, JacksonC.E, BarohnR.J, PtacekL.J. (1994). Paramyotonia congenita: Abnormal short exercise test,and improvement after mexiletine therapy. Muscle Nerve, 17, 763–768.
27.
KohT.H, & EyreJ.A. (1988). Maturation of corticospinal tractsassessed by electromagnetic stimulation of the motor cortex. Archives of Disease in Childhood, 63, 1347–1352.
LogigianE.L, MartensW.B, MoxleyR.T, McDermottM.P, Dilek,
N, WiegnerA.W, PearsonA.T, BarbieriC.A, AnnisC.L, ThorntonC.A, & Moxley IIIR.T. (2010). Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1 (LOE Classification). Neurology, 74, 1441–1448.
33.
LogigianE.L, MartensW.B, MoxleyR.T., 4th, McDermottM.P, DilekN, WiegnerA.W, PearsonA.T, BarbieriC.A, AnnisC.L, ThorntonC.A, & Moxley IIIR.T. (2010). Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology, 74, 1441–1448.
34.
MacdonellR.A, ShapiroB.E, ChiappaK.H, HelmersS.L, CrosD, DayB.J, & ShahaniB.T. (1991). Hemispheric thresholddifferences for motor evoked potentials produced by magnetic coilstimulation. Neurology, 41, 1441–1444.
MatthewsE, FialhoD, TanS.V, VenanceS.L, CannonS.C, SternbergD, FontaineB, AmatoA.A, BarohnR.J, GriggsR.C, HannaM.G, The CINCH. (2010). The non-dystrophicmyotonias: Molecular pathogenesis, diagnosis and treatment. Brain, 133, 9–22.
37.
MeolaG, & CardaniR. (2015). Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism. Journal of Neuromuscular Diseases, 2, S59–S71.
38.
WalshV. (2004). Plasticity in the human nervoussystem— investigations with transcranial magnetic stimulation. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 795–796.
39.
MioshiE, DawsonK, MitchellJ, ArnoldR, & HodgesJ.R. (2006). The Addenbrooke’s Cognitive Examination revised (ACE-R): Abrief cognitive test battery for dementia screening. International Journal of Geriatric Psychiatry, 21, 1078–1085.
40.
MohammadiB, Jurkat-RottK, AlekovA, DenglerR, BuflerJ, & Lehmann-HornF. (2005). Preferred mexiletine block of human sodium channels with IVS4 mutations andits pH-dependence. Pharmacogenetics and Genomics, 15, 235–244.
41.
OliveriM, BrighinaF, La BuaV, AloisioA, BuffaD, & FierroB. (1997). Magnetic stimulation study in patients withmyotonic dystrophy. Electroencephalography and Clinical Neurophysiology, 105, 297–301.
42.
OrthM, & RothwellJ.C. (2004). The cortical silent period:Intrinsic variability and relation to the waveform of thetranscranial magnetic stimulation pulse. Clinical Neurophysiology, 115, 1076–1082.
43.
Pascual-LeoneA, NguyetD, CohenL.G, Brasil-NetoJ.P, CammarotaA, & HallettM. (1995). Modulation of muscle responsesevoked by transcranial magnetic stimulation during the acquisitionof new fine motor skills. Journal of Neurophysiology, 74, 1037–1045.
44.
PortaroS, AltamuraC, LicataN, CamerinoG.M, ImbriciP, MusumeciO, RodolicoC, Conte CamerinoD, ToscanoA, & DesaphyJ.F. (2015). Clinical, molecular, and functional characterization of CLCN1 mutations in three families with recessivemyotonia congenita. Neuromolecular Medicine, 17, 285–296.
45.
PortaroS, DavisM.B, HaworthA, & HannaM.G. (2013). Prevalence study of genetically defined skeletal musclechannelopathies in England. Neurology, 80, 1472–1475.
46.
PortaroS, NaroA, ChilluraA, BilleriL, BramantiA, BramantiP, RodolicoC, & CalabròR.S. (2017). Toward amore personalized motor function rehabilitation in Myotonicdystrophy type 1: The role of neuroplasticity. PLoS One, 12(5), e0178470.
47.
QuartaroneA, RizzoV, BagnatoS, MorganteF, Sant’AngeloA, GirlandaP, & SiebnerH.R. (2006). Rapid-rate pairedassociative stimulation of the median nerve and motor cortex canproduce long-lasting changes in motor cortical excitability inhumans. The Journal of Physiology, 575, 657–670.
48.
RiddingM.C, & RothwellJ.C. (1997). Stimulus/response curves asa method of measuring motor cortical excitability in man. Electroencephalography and Clinical Neurophysiology, 105, 340–344.
49.
RodenD.M. (2001). Antiarrhythmic drugs. In: HardmanJ.G., LimbirdL.E., MolinoffB., RuddonR.W., GilmanA.G. (Eds). Goodman and Gilman’s the Pharmacological Basis of Therapeutics (pp. 933–970), New York: Macmillan Publishing Co.
50.
RossiniP.M, BarkerA.T, BerardelliA, CaramiaM.D, CarusoG, CraccoR.Q, …TombergC. (1994). Non-invasive electrical and magnetic stimulation of the brain, spinal cord androots: Basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalography and Clinical Neurophysiology, 91, 79–92.
51.
SansoneV.A. (2016). The dystrophic and nondystrophic myotonias. CONTINUUM Lifelong Learning in Neurology, 22, 1889–1915.
52.
SchwartzP.J, PrioriS.G, LocatiE.H, NapolitanoC, CantúF, TowbinJ.A, KeatingM.T, HammoudeH, BrownA.M, ChenL.S, & ColatskyT.J. (1995). Long QT syndromepatients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate.Implications for gene-specific therapy. Circulation, 92, 3381–3386.
ShenY, CaoX, TanT, ShanC, WangY, PanJ, HeH, & YuanT.F. (2016). 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex ReducesHeroin Cue Craving in Long-Term Addicts. Biological Psychiatry, 80, e13–e14.
55.
SiebnerH.R, DressnandtJ, AuerC, & ConradB. (1998). Continuous intrathecal baclofen infusions induced a marked increaseof the transcranially evoked silent period in a patient withgeneralized dystonia. Muscle Nerve, 21, 1209–1212.
56.
StatlandJ.M, BundyB.N, WangY, RayanD.R, TrivediJ.R, SansoneV.A, SalajeghehM.K, VenanceS.L, CiafaloniE, MatthewsE, MeolaG, HerbelinL, GriggsR.C, BarohnR.J, HannaM.G, Consortium for Clinical Investigation of NeurologicChannelopathies. (2012). Mexiletine for symptoms and signs ofmyotonia in non-dystrophic myotonia: A randomized controlled trial. The Journal of the American Medical Association, 308, 1357–1365.
57.
StefanK, KuneschE, BeneckeR, CohenL.G, & ClassenJ. (2002). Mechanisms of enhancement of human motor cortex excitabilityinduced by interventional paired associative stimulation. The Journal of Physiology, 543, 699–708.
58.
StysP.K, & LesiukH. (1996). Correlation between electrophysiological effects of mexiletine and ischemic protectionin central nervous system white matter. Neuroscience, 71, 27–36.
59.
SunC, Van GhelueM, TranebjærgL, ThyssenF, NilssenØ, & TorbergsenT. (2011). Myotonia congenita and myotonicdystrophy in the same family: Coexistence of a CLCN1 mutation andexpansion in the CNBP (ZNF9) gene. Clinical Genetics, 80, 574–580.
60.
SunamiA, FanZ, SawanoboriT, & HiraokaM. (1993). Use-dependent block of Na+ currents by mexiletine at the singlechannel level in guinea-pig ventricular myocytes. British Journal of Pharmacology, 110, 183–192.
61.
SuominenT, SchoserB, RaheemO, AuvinenS, WalterM, KraheR, LochmüllerH, KressW, & UddB. (2008). Highfrequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. Journal of Neurology, 255, 1731–1736.
62.
TaylorC.P, & MeldrumB.S. (1995). Na+ channels as targets forneuroprotective drugs. Trends in Pharmacological Sciences, 16, 309–316.
63.
WangG.K, RussellC, & WangS.Y. (2004). Mexiletine block ofwild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels. The Journal of Physiology, 554, 621–633.
64.
WerhahnK.J, KuneschE, NoachtarS, BeneckeR, ClassenJ. (1999). Differential effects on motor cortical inhibition inducedby blockade of GABA uptake in humans. The Journal of Physiology, 517, 591–597.
